Literature DB >> 16932287

Mechanisms of disease: The pathogenesis of pituitary tumors.

Shereen Ezzat1, Sylvia L Asa.   

Abstract

Pituitary tumors exhibit a spectrum of biology, with variable growth and hormonal behaviors. They therefore provide an opportunity to examine pathogenetic mechanisms that underlie the neoplastic process. These include alterations in hormone regulation, growth-factor stimulation, cell-cycle control and cell-stromal interactions that result from genetic mutations or epigenetic disruption of gene expression. Mouse models have validated the roles of these alterations, which can be targets for the development of therapies that can manage these lesions. These therapies are increasingly recognized as critical for quality of life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932287     DOI: 10.1038/ncpendmet0159

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  25 in total

Review 1.  MicroRNAs in the human pituitary.

Authors:  Milani Sivapragasam; Fabio Rotondo; Ricardo V Lloyd; Bernd W Scheithauer; Michael Cusimano; Luis V Syro; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

2.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

Review 3.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

4.  Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors.

Authors:  D Schult; A Hölsken; M Buchfelder; S-M Schlaffer; S Siegel; I Kreitschmann-Andermahr; R Fahlbusch; R Buslei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

5.  p21(Cip1) restrains pituitary tumor growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kalman Kovacs; Anat Ben-Shlomo; Kolja Wawrowsky; Serguei Bannykh; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

6.  MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.

Authors:  Kai Zhou; Tingrong Zhang; YanDong Fan; Guojia Du; Pengfei Wu; Dangmurenjiafu Geng
Journal:  Tumour Biol       Date:  2016-07-27

7.  Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  US Endocrinol       Date:  2009-02-01

8.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Roger Gejman; Dalia L Batista; Ying Zhong; Yunli Zhou; Xun Zhang; Brooke Swearingen; Constantine A Stratakis; E Tessa Hedley-Whyte; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

10.  Craniocaudal extension as an indication of surgical outcome in transsphenoidal surgery for pituitary adenomas.

Authors:  Ossama Hamid; Adel El Hakim; Hossam El Husseiny; Lobna El Fiky; Sherif Kamel
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.